Commissioners - Commission on Human Medicines

Closed
Body: Department of Health and Social Care
Appointing Department: Department of Health
Sector: Health
Location: London
Number of Vacancies: 6
Remuneration: The Commissioners are remunerated at the standard rate of £325 per meeting.
Time Requirements: Approximately 22 days per year, including 11 meetings and any ad-hoc meetings based on need.

Campaign Timeline

  • Competition Launched

    12/10/2020

  • Closed for Applications

    23/11/2020 at 12:00

  • Panel Sift

    07/12/2020

  • Final Interview Date

    11/02/2021

  • Announcement

    TBC

 

Assessment Panel

  • Stephen Lightfoot Added 12/10/2020

    Panel Chair

    Chair of the Medicines and Healthcare products Regulatory Agency • Representative of Organisation

    Show more information

  • Dr June Raine Added 12/10/2020

    CEO of the Medicines and Healthcare products Regulatory Agency • Representative of Organisation

    Show more information

  • Professor Sir John Bell Added 12/10/2020

    Regius Professor of Medicine, Oxford University • Other Panel Member

    Show more information

  • Rima Makarem Added 12/10/2020

    Non-Executive Director, National Institute for Health and Care Excellence • Independent Member

    Show more information

Vacancy Description

Ministers are seeking to make 6 appointments to the board of the CHM.

Role and Responsibilities of a Commissioner

Commissioners are required to:

  • possess or develop a working knowledge and understanding of the UK medicines regulatory procedures
  • attend all scheduled and unscheduled meetings of the CHM (and to be present for the whole meeting)
  • consider, comment and contribute by drawing on their individual expertise and judgement, as appropriate, on all agenda items and to assist the CHM to frame clear and unequivocal advice to Ministers in accordance with the CHM’s terms of reference
  • be able and prepared to speak on a range of relevant issues and not just on their own areas of specialism
  • provide formal and informal advice to Ministers between meetings when required
  • contribute to and ensure the CHM’s advice takes account of a wider view of risk and benefit, particularly as it is perceived by patients, carers and other members of the public

Person Specification

The Department of Health and Social Care values and promotes diversity and encourages applications from all sections of the community. The boards of public bodies should reflect the population they are there to serve. Boards also benefit from fresh perspectives, and we are always keen to encourage candidates with private sector experience to consider applying for our roles.

Essential Criteria

To be considered, you must be able to demonstrate that you have the qualities, skills and experience to meet all the essential criteria for appointment.

  • ability to operate effectively on a national expert scientific committee
  • be skilled communicators
  • ability to assimilate complex scientific information at short notice
  • ability and prepared to contribute actively to the work of the CHM

 

In addition, for the six specialist posts successful candidates should be recognised by their peers and/or be Fellows of the relevant Royal Colleges in one of the following areas:

  • pharmacogenomics/pharmacogenetics;
  • in clinical pharmacology/ pharmacovigilance;
  • epidemiology and clinical trials;
  • a nurse specialist;
  • an expert in pharmacy and standards;
  • a toxicologist;
  • paediatrician or paediatric specialist

We may also require additional expertise of a psychiatrist.

Additional Information

The functions of the CHM are:

  • To advise Ministers on matters relating to human medicinal products (except those that fall under the remit of The Advisory Board on the Registration of Homeopathic Products (ABRHP) and the Herbal Medicines Advisory Committee (HMAC) including giving advice in relation to the safety, quality and efficacy of human medicinal products, where either the CHM think it appropriate or where it is asked to do so.
  • To advise the Licensing Authority (LA) where the LA has a duty to consult the CHM or where the LA chooses to consult the CHM
  • To consider representations made in relation to the CHM’s advice (either in writing or at a hearing) by an applicant or by a licence or Marketing Authorisation (MA) holder; and;
  • to promote the collection and investigation of information relating to adverse reactions for human medicines (except for those products that fall within the remit of ABRHP or HMAC) for the purposes of enabling such advice to be given.

Background on some aspects of the CHM’s work

An annual report is produced at the end of each calendar year which is laid before parliament and made public. A link to the 2019 report is available through the Gov.UK website: https://www.gov.uk/government/publications/human-medicines-regulations-2012-advisory-bodies-annual-report-2019

Attachments
14.1 diversity-monitoring-form
15. GIS_Form
12.1 DHSC_Privacy-notice-v03
VAC-1725 Commissioners Info Pack v.final
Return to Search